Getting melanoma chemotherapy to work | Science News

Support Science Journalism

Science News is a nonprofit.

Support us by subscribing now.


Getting melanoma chemotherapy to work

1:21pm, October 4, 2002

From San Francisco, at the 91st Annual Meeting of the American Association for Cancer Research

People with the skin cancer called melanoma respond poorly to chemotherapy. Austrian researchers now report that a drug known as G3139 can turn off a gene that underlies this resistance.

This gene, bcl-2, produces a protein that shields tumor cells from chemotherapy by thwarting the programmed cell death, or apoptosis, that these drugs induce in rapidly dividing cells.

G3139 is a mixture of synthesized DNA pieces "that basically glue themselves to RNA and prevent the Bcl-2 protein from being produced," says clinical pharmacologist Burkhard Jansen of the University of Vienna, who reported the findings.

Among 14 patients treated with chemotherapy and G3139 for advanced melanoma, remission occurred in one person, tumors shrank by more than half in two others, and tumors decreased somewhat less in another three, Jansen says. On average, the 14 patient

This article is only available to Science News subscribers. Already a subscriber? Log in now.
Or subscribe today for full access.

Get Science News headlines by e-mail.

More from Science News

From the Nature Index Paid Content